arrow
K

Kirit M. Ardeshna

ucsf medical center
H指数:36
被引数:5,851

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up

利索卡巴肽马瑞克塞尔(liso-cel)在复发或难治性(R/R)滤泡性淋巴瘤(FL)患者(pts)中的2年随访:超越FL研究

BLOOD
IF23.1
2024-11-050
PRE
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study (JUL, 10.1038/s41591-024-02986-9, 2024)
2024-07-094
OAAI
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study
2024-06-039
OAAI
Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma (vol 34, pg 2184, 2020)
LEUKEMIA
IF13.4
2024-01-100
OAAI
Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial

在LOTIS-2临床试验中接受loncastuximab tesirine治疗的老年和年轻患者的临床结果

2023-12-282
OAAI
Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study
2023-11-1510
OAAI
PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial

PET/CT生物标志物可对参加LOTIS-2临床试验的复发/难治性弥漫性大b细胞淋巴瘤患者进行风险分层

2023-10-194
OA
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study

Loncastuximab tesirine治疗复发/难治性弥漫大B细胞淋巴瘤:II期LOTIS-2研究的长期疗效与安全性

2023-08-3128
OAAI
The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms (vol 36, pg 1720, 2022)

世界卫生组织第5版血淋巴肿瘤分类: 淋巴肿瘤 (第36卷,1720页,2022)

LEUKEMIA
IF13.4
2023-07-1915
OAAI
The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study

iR2方案 (伊布替尼 + 来那度胺和利妥昔单抗) 治疗复发/难治性DLBCL: 一项多中心、非随机、开放标签的2期研究

2023-02-0112
OAAI
Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study

Loncastuximab tesirine治疗复发/难治性高级别b细胞淋巴瘤: 来自LOTIS-2研究的亚组分析

2022-08-161
OAAI
Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study

自体EBV特异性T细胞治疗可导致晚期结外NK/T淋巴瘤患者的持续反应: 多中心研究的结果

2021-07-2419
PREAI
Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma
LEUKEMIA
IF13.4
2020-02-1449
OAAI
CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial
2018-05-0153
OAAI
Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial
2017-07-0137
OAAI